Recovering GlaxoSmithKline plc Won’t Be Cheap For Much Longer

There are still dangers, but they are also reflected in GlaxoSmithKline plc (LON:GSK)’s share price

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gsk

Pharmaceutical giant GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) is one of those rock-solid stocks that you despair of being able to pick up at a bargain price.

It has routinely traded comfortably above 15 times earnings, with only very occasional slippage. But following recent travails, it is suddenly available at the bargain price of just 12.55 times earnings.

If that tempts you, you might want to act fast. Because Glaxo’s share price is already starting to recover and could soon be back to rude health.

I Feel Fine

Frankly, I’m amazed we have this opportunity at all. Then again, I hadn’t expected this reputable company to get caught up in a string of bribery and corruption scandals in China and beyond.

Glaxo got off relatively lightly in China with a £300m fine, but it may still face costly spin-off investigations in the US and UK.

As its stock is traded on US exchanges, it is vulnerable under the US Foreign Corrupt Practices Act, which is worrying, given the US propensity to slap massive fines on foreign companies.

Although with Glaxo leading the chase for an Ebola vaccine, the US may take a more benign view. Given the media frenzy, the authorities won’t want to do anything that might delay the drug’s release.

Big In Japan

The bribery scandal isn’t the only reason Glaxo is trailing. Profits have been down lately, although recent Q3 results were better than many analysts feared. 

Core operating profits fell 6% to £1.89bn, but it could have been worse, with markets expecting a bigger drop to £1.71bn. 

So there are still dangers, but they are also reflected in Glaxo’s share price, which is down 15% over the last six months, against a drop of just 4.5% on the FTSE 100 as a whole.

Glaxo is also fighting back with an ambitious cost-cutting plan, which should generate £1bn of savings every year for the next three years. Its long-term R&D and product helpline looks promising, and sales are growing strongly in emerging markets and Japan.

Today, you can buy into those recovery prospects at a mouth-watering discount.

One Mighty Yield

Glaxo may not be this cheap much longer, with the share price up more than 4% in the last week. But this still a good price, while the yield is a mighty 5.51%, one of the most generous on the FTSE 100.

Those numbers are worth repeating. Glaxo is available at 12.55 times earnings and offers a yield of more than 11 times Bank of England base rate.

This opportunity to load up on this long-standing FTSE favourite probably won’t last long, so don’t squander it.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »